<DOC>
	<DOCNO>NCT00071851</DOCNO>
	<brief_summary>The purpose study test safety immune response HIV-1 vaccine , VRC-HIVDNA009-00-VP , HIV uninfected participant . Two different dos vaccine test .</brief_summary>
	<brief_title>Safety Immune Response HIV-1 DNA Vaccine ( VRC HIVDNA009-00-VP ) HIV Uninfected Adults</brief_title>
	<detailed_description>The worldwide HIV epidemic highlight importance develop affordable , globally successful vaccine HIV prevention . The VRC-HIVDNA009-00-VP vaccine use study develop incorporate HIV gene multiple virus clade , represent viral subtypes responsible 90 % new HIV infection world . The purpose study determine safety immunogenicity VRC-HIVDNA009-00-VP healthy , HIV uninfected individual . Participants randomly assign one three group follow one year . Study injection give needle-free intramuscular injection start study Months 1 2 . Group 1 receive 3 injection study vaccine ; Group 2 receive 2 injection study vaccine ( start Month 2 ) injection placebo ( Month 1 ) ; Group 3 receive 3 injection placebo . After screen visit , study visit occur enrollment ( initial injection ) follow 5 visit every 14 day first 2.5 month , three additional visit Months 6 , 9 , 12 . All participant undergo physical exam , blood urine test assess measure health , blood test assess HIV infection immune response injection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Understanding vaccination procedure Willing receive HIV test result provide informed consent Good general health HIV negative Hepatitis B surface antigen negative Antihepatitis C virus ( HCV ) antibody negative , negative HCV PCR antiHCV positive Not pregnant agrees use acceptable form contraception Exclusion Criteria HIV vaccine placebo prior HIV vaccine trial Immunosuppressive medication within 168 day prior study Blood product within 120 day prior study Immunoglobulin within 60 day prior study Live attenuate vaccine within 30 day prior study Investigational research agent within 30 day prior study Medically indicate subunit kill vaccine within 14 day prior study Current antituberculosis prophylaxis therapy Anaphylaxis serious adverse reaction vaccine ; person adverse reaction pertussis vaccine child exclude Autoimmune disease immunodeficiency Active syphilis infection Unstable asthma ( e.g. , use oral , orally inhale , intravenous corticosteroid , emergent care , urgent care , hospitalization intubation past 2 year ) Diabetes mellitus ; participant past gestational diabetes exclude Thyroid disease , include removal thyroid diagnose require medication Serious angioedema Hypertension Diagnosis bleed disorder Malignancy , except surgical excision subsequent observation period investigator 's estimate reasonable assurance sustain cure and/or unlikely recur period study Seizure disorder require medication within last 3 year Absence spleen Mental illness would interfere compliance protocol Pregnant breastfeed Two elevate liver function test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>